It is shown that a single high-dose SC immunization of A/Puerto Rico/8/34 (H1N1) elicited sterile pulmonary immunity against lethal challenge, significantly outperforming intramuscular delivery and inactivated vaccines.
Abstract
Current influenza vaccination strategies are constrained by the trade-off between the safety of inactivated platforms and the immunogenic potency of live attenuated vaccines. Here, we provide a comprehensive demonstration that subcutaneous (SC) immunization with a non-attenuated, replication-competent live influenza A virus (LIV) decouples immunogenicity from pathogenicity. Using a murine model, we show that a single high-dose SC immunization of A/Puerto Rico/8/34 (H1N1) elicited sterile pulmonary immunity against lethal challenge, significantly outperforming intramuscular delivery and inactivated vaccines. Biodistribution analysis confirms viral replication is transient (<7 days) and strictly restricted to the injection site and draining lymph nodes, with no systemic dissemination to the lungs or central nervous system. Mechanistically, single-cell transcriptomics reveal that SC delivery triggers a localized type I interferon "firewall" that transitions into a robust germinal center (GC) reaction, fostering extensive plasma cell differentiation and superior memory B cell formation compared to phosphate-buffered saline (PBS)-treated controls. This regimen conferred 100% protection at 277 days post-immunization. Together, these findings establish peripheral LIV administration as a high-potency paradigm for next-generation rapid-response vaccines.
Respiratory infectious diseases remain a major global health burden, sustained by ongoing community transmission. Licensed respiratory vaccines are predominantly systemically administered, which elicit vaccine-induced antigen-specific circulating immunity, but fail to protect the primary site of initial infection and o...
R. Fraser, Jürgen Schwarze, D. Dockrell· Frontiers in Immunology· 0 citations
Respiratory syncytial virus (RSV) remains a major cause of severe lower respiratory tract disease in infants, older adults, and immunocompromised individuals, underscoring the need for vaccine strategies that balance systemic protection with frontline respiratory immunity. Although adenoviral and RNA-based RSV are both...
Yao Zhang, Yu Qin, Zhong-Bing Qi et al.· EMBO Molecular Medicine· 0 citations
Abstract Despite the rising burden of invasive fungal disease, no fungal vaccine is available to use. Cryptococcus neoformans is a fungal pathogen that initiates pulmonary infection and can disseminate to cause fatal meningoencephalitis. We previously identified HK-fbp1, a heat-inactivated C. neoformans mutant strain l...
Yu Zhang, Yi-Na Wang, Ke-Yi Wang et al.· Research Square· 0 citations
Nucleic acid vaccines offer rapid and flexible platforms for addressing infectious diseases but achieving durable and balanced immunity remains a challenge. We evaluated a closed linear synthetic Doggybone™ DNA vaccine (dbDNA™) encoding influenza A/California/07/2009 hemagglutinin across delivery platforms and preclini...
Helen Horton, Robert F. Cunliffe, Sungwon Kim et al.· Molecular Therapy· 0 citations
Background: Emerging and re-emerging infectious diseases pose a growing global threat, underscoring the need for vaccine platforms enabling rapid deployment and durable, broad protection. Although mRNA and viral vector vaccines transformed pandemic responses, limitations include waning immunity, restricted antigenic br...
Joshua Wiggins, Adthakorn Madapong, Eric A. Weaver· Vaccines· 0 citations
Parenteral vaccines against respiratory viruses poorly block infection and transmission due to suboptimal induction of mucosal immunity. In contrast, hybrid immunity and heterologous-route immunization regimens generate protective mucosal and systemic immunity. Herein, we examine how chronological order in heterologous...
Matthew J. Wiest, Gabriel Laghlali, Julianne d'Acunzo et al.· EMBO Molecular Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.